|Summary sheet: MiPT|
|Routes of Administration|
N-Methyl-N-isopropyltryptamine (also known as MiPT) is a lesser-known psychedelic substance of the tryptamine class that produces psychedelic effects when administered. It is structurally related to tryptamines like DMT, DiPT, and MET, although it is reported to produce qualitatively different effects. Its effects are generally described as mild, indistinct, and highly variable between users. In contrast to many related tryptamines, it is able to be taken orally.
MiPT was first synthesized and investigated by Alexander Shulgin and described in his book TiHKAL ("Tryptamines I Have Known and Loved"). In the commentary, Shulgin notes that "there is almost a total lack of visual phenomena... no wave-forms, color distortion or object shape changes, and no eyes-closed imagery, unlike most N,N-disubstituted tryptamines."
Today, MiPT remains relatively uncommon and is either used as a recreational or an entheogenic substance. It has been distributed online as a research chemical. Very little data exists about the pharmacological properties, metabolism, and toxicity of MiPT in humans, and it has little history of human usage.
MiPT is the methyl analog of DiPT.
Like with most psychedelic tryptamines, MiPT is thought to act principally as a 5-HT2A partial agonist. The psychedelic effects are believed to come from MiPT's binding efficacy at the 5-HT2A receptors.
However, the role of these interactions and how it results in the psychedelic experience continues to remain elusive.
The sensory effects of MiPT are said to be similar to those of DiPT but with less intensity at the same dose, and without the same bias towards producing auditory distortions.
Disclaimer: The effects listed below are cited from the Subjective Effect Index (SEI), which relies on assorted anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be taken with a healthy amount of skepticism. It is worth noting that these effects will not necessarily occur in a consistent or reliable manner, although higher doses (common+) are more likely to induce the full spectrum of reported effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.
- The cognitive effects of MiPT are reported to be mild for a psychedelic. Rather than producing distinct perceptual distortions, it is reported instead to act as a mild sensory amplifier.
There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:
Toxicity and harm potential
The toxicity and long-term health effects of recreational MiPT use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because MiPT is a research chemical with very little history of human usage.
Anecdotal evidence from those who have tried MiPT suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this drug.
Tolerance and addiction potential
MiPT is not habit-forming and the desire to use it can actually decrease with regular consumption. Like with most psychedelics, it is most often thought to be self-regulating.
Tolerance to the effects of MiPT are built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). MiPT presents cross-tolerance with all psychedelics, meaning that after the consumption of MiPT all psychedelics will have a reduced effect.
Due to its relative obscurity, the possession and sale of MiPT is unscheduled in most countries.
- Germany: MiPT is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
- United Kingdom: MiPT is a Class A controlled substance in the United Kingdom as a result of the tryptamine catch-all clause.
- United States: MiPT is unscheduled in the United States. It may be considered an analogue of DMT, which is a Schedule I compound under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.
This article does not cite enough references.
You can help by adding some.
- Shulgin, Alexander; Shulgin, Ann (1997). "#47. MIPT". TiHKAL: The Continuation. United States: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252.
- "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
- "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. Retrieved January 1, 2020.
- "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
- "Part I: Class A Drugs". "Misuse of Drugs Act 1971". UK Government. Retrieved January 7, 2020.